Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2157299 with or without lomustine versus lomustine in recurrent glioblastoma
NL-OMON37449Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2013
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in glioblastoma (GBM) comparing galunisertib monotherapy, galunisertib plus lomustine and lomustine plus placebo (3 arms). Primary endpoint: Overall survival. Started Feb 2013; status: active, not recruiting.
02
Drugs
galunisertiblomustine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON37449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37449.